Intellipharmaceutics International Inc. (IPCI)

[Laloo77]

WOODCLIFF LAKE, N.J., Nov. 20, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has begun shipping dexmethylphenidate hydrochloride (HCl) 15 mg and 30 mg extended-release (ER) capsules CII following approval by the U.S. Food and Drug Administration. As marketer and distributor, Par will have 180 days of marketing exclusivity for the 15 mg strength and will share profits with its development partner.

Dexmethylphenidate HCl ER is the generic version of Novartis' Focalin XR® and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. According to IMS Health data, annual U.S. sales of the Focalin XR® 15 mg and 30 mg strengths are approximately $202 million.

http://www.prnewswire.com/news-releases/par-pharmaceutical-begins-shipment-of-generic-focalin-xr-capsules-232651641.html